A Phase II Evaluation of a Urokinase-Derived Peptide (A6) (IND 64,298) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

Trial Profile

A Phase II Evaluation of a Urokinase-Derived Peptide (A6) (IND 64,298) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Jan 2015

At a glance

  • Drugs A 6 (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 08 Aug 2012 Actual end date (1 Jul 2012) added as reported by ClinicalTrials.gov.
    • 01 Jul 2012 Status changed from suspended to completed as reported by ClinicalTrials.gov.
    • 30 Jan 2010 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top